Michael Javaheri, MD, MSc, FASRS

Rapid early disease control may establish the trajectory for long-term outcomes in neovascular AMD, supporting first-line use of second-generation anti-VEGF agents in patients with high-risk anatomic or functional features.

A new diagnosis of neovascular age-related macular degeneration carries consequences well beyond visual acuity, and early treatment goals must balance anatomic disease control with patient confidence and long-term adherence.